Syndesi swallowed by Abbvie

Originally, Belgian Syndesi was created in 2017 through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors led by Novo Holdings to advance UCB’s SV2A modulator SDI-118. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a central role in regulating neurotransmission.

SDI-118 is currently evaluated in Phase Ib studies as a imodulator of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder.  

Under the terms of the agreement, AbbVie will pay Syndesi a $130m upfront and potential  milestone payments of up to $870m.